Sanofi India Q2 FY26: Diabetes momentum lifts profits as costs stay tight

Sanofi India used the June 2026 quarter to show what its reshaped business can do when execution and cost control move together. Total income for Q2/2026 rose to ₹4,439 million, up 7 percent year on year, led by a 6 percent increase in sales to ₹4,162 million. Underneath that steady top line, the domestic franchise delivered a clearer message. Domestic net sales grew 8 percent to ₹3,559 million, and the mix tilted further toward diabetes, where the company is pushing both scale and innovation.

Profitability improved faster than revenue. Profit before tax and exceptional items increased 19 percent year on year to ₹1,123 million in Q2/2026, compared with ₹941 million in Q2/2025. As a share of net sales, this moved to 27 percent from 24 percent. The company tied the margin expansion to tighter operating expenses and continued optimization of resources, a theme repeated through the presentation.

The quarter also provided a contrast with the half-year picture. For the first half ended June 2026, total income fell 4 percent to ₹9,206 million. Domestic net sales for H1/2026 declined 2 percent to ₹7,528 million, which management attributed to a one-off impact in the prior year. Even with that drag, the company held profit before tax and exceptional items at 29 percent of net sales for both H1/2025 and H1/2026, indicating that the cost discipline visible in Q2 was not only a one-quarter event.

Revenue mix shows diabetes driving the story

Sanofi India presented its domestic performance in euro terms to emphasize mix and momentum. Domestic revenue increased from €3.298 million in 2025 to €3.559 million in 2026, an 8 percent rise. Insulins expanded from €1.776 million to €2.031 million, taking the insulin share to 57 percent from 54 percent. Partnerships grew modestly from €1.423 million to €1.457 million, but their share slipped to 41 percent from 43 percent. Other declined to €71 million from €99 million.

The company linked the growth directly to its diabetes franchise, describing the quarter as strong momentum further boosted by the diabetes business. The commentary stressed that the diabetes business continues to grow above market growth and is supported by an innovative portfolio. The company also highlighted acceleration in the public sector, noting 70 percent growth tied to opening of new accounts for Toujeo and Soliqua. That focus matters because it signals expansion beyond the private channel into institutional demand where volume can scale, but where execution and access are critical.

The half-year domestic trend shows why management is leaning into diabetes and emphasizing execution. Total H1 domestic sales fell 2 percent to ₹7,528 million. Within that, insulin rose to ₹4,165 million from ₹3,559 million, while partnerships fell 15 percent to ₹3,224 million from ₹3,788 million. Other declined to ₹139 million from ₹304 million. In other words, the diabetes engine offset a sizable partnership decline, but could not fully overcome it for the full half-year.

Exports were another headwind in the background. For Q2, export sales declined 2 percent from 6.14 to 6.03 in the company’s presentation. For H1, export sales declined 7 percent from 1.243 to 1.162. The presentation did not detail the drivers, but it did state that partnerships were stabilizing while there were headwinds in the export business. This matters for investors because it frames the near-term performance as increasingly dependent on domestic execution, particularly within diabetes.

Financial summary

Notes: Other operating income mainly services. Other income mainly interest on deposit and foreign exchange gain.

Where scale meets innovation in diabetes

Sanofi positioned its diabetes franchise as a combination of market leadership, innovation-led differentiation, and channel extension. The company stated it holds 47 percent market share by value in the basal market and is seeing volume acceleration of 6 percent. It also called out its status as the preferred second generation basal insulin with 11 percent market share by value. Within basal analogs more broadly, it cited a market share of 58 percent by value and 61 percent by volume, based on IQVIA MAT June 2026.

What stands out is that the strategy is not only about defending share in a mature category. It is also about shaping demand and improving outcomes, which can support sustained pricing power and longer product life cycles. The presentation emphasized expanding the real-world evidence narrative and Indian datasets to strengthen Toujeo and Soliqua positioning. It referenced the LANDMARC real-world evidence study and scientific evidence dissemination with key opinion leader advocacy to address unmet need in India. It also mentioned Soliqua and Toujeo real-world evidence publications.

This clinical and evidence-led posture is paired with an operating model shift. The company described a transformed business model where strategic transformation is complete, with focus on insulin and a winning partnership model for legacy brands. The intent seems clear. Diabetes, anchored by insulins, provides growth and strategic priority. Partnerships, while still meaningful, are being managed for return on investment and footprint expansion rather than as the main growth engine.

The extension leg of the value proposition centers on the public sector. Sanofi highlighted entry in CARE accounts, with a 70 percent growth linked to the innovative diabetes portfolio, and digital outreach into Tier II and Tier III markets. For investors, this is a signal that the company believes it can expand access and coverage without losing its margin profile, although execution risks tend to be higher in public channels.

Segment comparison, domestic net sales

Cost discipline turns growth into profit

Sanofi’s margin expansion in Q2 was supported by operating expense control. Total operating expenses excluding depreciation and finance cost declined from ₹1,027 million in Q2/25 to ₹972 million in Q2/26. Employee costs moved from ₹449 million to ₹446 million, while other operating expenses dropped from ₹578 million to ₹526 million.

The first-half comparison shows the same direction. Total operating expenses declined from ₹2,262 million in H1/25 to ₹1,923 million in H1/26. Employee costs fell 15 percent from ₹987 million to ₹874 million, and other operating expenses fell from ₹1,275 million to ₹1,050 million. Management framed this as increased focus on financial discipline and optimization.

These cost numbers matter because they explain why profit growth outpaced revenue growth in Q2. They also help explain the stability in profit margin across the half year even when total income declined. In practical terms, the company is showing it can protect profitability during a period when partnerships and exports face pressure, while still funding priority areas in diabetes.

Management’s broader narrative ties cost discipline to organizational and capability changes. The company highlighted building the right capabilities with leadership changes and a focus on AI readiness through an initiative called AI Samvaad. It also pointed to future-ready go-to-market capabilities, a customer-centric approach, AI-enabled initiatives, and innovative customer journey orchestrations. The presentation did not quantify the financial impact of these initiatives, but it positioned them as part of the operating system that supports execution and efficient growth.

ESG and access: CSR as a parallel track

The presentation included a CSR update framed around community impact, particularly in diabetes and primary health access. Under the Kids and Diabetes in Schools program, the company stated that more than 600,000 direct beneficiaries are to be reached in 2026. It also provided interim scale markers for H1 2026, including 400 plus schools, 450 plus teachers, and 80,000 plus students, with the note that the academic year begins in June.

For mobile medical units, the company cited 156,000 plus people screened, 71,000 plus diagnosed, and 64,000 plus treated. It also stated that 5,000 plus were counselled for lifestyle modification and referred to primary health centers for further treatment.

The company also referenced a memorandum of understanding signed with the National Health Mission in Madhya Pradesh, including Kids and Diabetes in Schools piloted in Bhopal, mobile medical units planned for the second half, and strengthening of the rare disease ecosystem. While these initiatives are not presented as revenue drivers, they align with the business focus on diabetes and public health and can support long-term trust with stakeholders.

What investors should take away

Sanofi India’s June 2026 quarter was defined by two reinforcing trends. First, the domestic diabetes engine is gaining share of the mix and showing strong momentum, supported by public sector expansion and evidence-led positioning for Toujeo and Soliqua. Second, the company is turning that momentum into profit through operating expense discipline, which lifted Q2 profit before tax and exceptional items by 19 percent and expanded margin to 27 percent of net sales.

The half-year numbers show a more complex picture, with total income down 4 percent and domestic net sales down 2 percent, weighed by partnership declines and export headwinds. But the company held profitability at 29 percent of net sales for the half year, suggesting resilience in the model.

The quarterly theme is disciplined execution with clear priorities. Management is focusing on insulin-led growth, stabilizing partnerships, and building future-ready capabilities including AI readiness and modern go-to-market execution. If diabetes continues to outpace the market and public sector access keeps expanding without sacrificing cost control, the company’s Q2 margin profile offers a credible base for sustained profitability.